TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22908174

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Daptomycin 8 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparator (vancomycin, teicoplanin, or semisynthetic penicillin)
Number of subjects: 75
Study: 19474650

Group type: EXPERIMENTAL
Intervention: DRV/r (darunavir/ritonavir) 600/100 mg twice daily
Number of subjects: 595
Study: 17560880

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15191881

Group type: EXPERIMENTAL
Intervention: Erythromycin (1 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 10
Study: 12692749

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril, 20 mg o.d. for two years)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9888904

Group type: EXPERIMENTAL
Intervention: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services (7 to 12 individual treatment sessions from a research psychologist plus routine care)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services
Number of subjects: 69
Study: 7741619

Group type: EXPERIMENTAL
Intervention: AC iontophoresis for 4 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AC iontophoresis for 2 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control patch (not activated)
Number of subjects: 10
Study: 1952199

Group type: EXPERIMENTAL
Intervention: Therapeutic suggestions (tape recording predicting smooth recovery)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control (blank tape)
Number of subjects: 209
Study: 7102768

Group type: EXPERIMENTAL
Intervention: 100 mg of oral sulpiride for 4 days from the third postpartum day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo for 4 days from the third postpartum day
Number of subjects: 96
Study: 29438156

Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity - Cognitive Concerns
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity - Physical Concerns
Number of subjects: 470
Study: 27467700

Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy (FPT)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavior therapy (CBT‐E)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Optimized treatment as usual (TAU‐O)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 169
Study: 23700142

Group type: EXPERIMENTAL
Intervention: Multiple plasma amino acid index (API)
Number of subjects: 442

Group type: COMPARATOR
Intervention: CA125
Number of subjects: 442
Study: 22489894

Group type: EXPERIMENTAL
Intervention: BAK-preserved timolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Preservative-free timolol
Number of subjects: 28
Study: 20298823

Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise program including aerobic training, strength training, and group sport
Number of subjects: 147

Group type: COMPARATOR
Intervention: Submaximal testing with heart rate <140 bpm
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Submaximal testing with heart rate >=140 bpm
Number of subjects: 147
Study: 17532576

Group type: EXPERIMENTAL
Intervention: Presence of alcohol
Number of subjects: 213

Group type: COMPARATOR
Intervention: No alcohol presence
Number of subjects: 213

Group type: COMPARATOR
Intervention: Resistance type
Number of subjects: 213

Group type: COMPARATOR
Intervention: Participant gender
Number of subjects: 213
Study: 16235869

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (4-6 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 12022095

Group type: EXPERIMENTAL
Intervention: High-resolution ultrasonography (HR-US) at closed-mouth position
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-resolution ultrasonography (HR-US) at maximum-mouth opening position
Number of subjects: 29
Study: 9620110

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacologic interventions (general)
Number of subjects: 0
Study: 8092084

Group type: COMPARATOR
Intervention: 0.80 g protein.kg‐1.d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.62 g protein.kg‐1.d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined data from current and previous studies
Number of subjects: 12
Study: 2803624

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 16 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nonaerobic exercise (yoga)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 85
Study: 4424007

Group type: EXPERIMENTAL
Intervention: Gallbladder bile
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hepatic bile
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bile from non-functioning gallbladders
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bile with cholesterol crystals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bile analysis
Number of subjects: 30
Study: 30681490

Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 28625384

Group type: EXPERIMENTAL
Intervention: ≥2 appropriate shocks
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: ≥2 inappropriate shocks
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: ≥2 appropriate ATPs
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: ≥2 inappropriate ATPs
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Appropriate or inappropriate ATP/shock
Number of subjects: 1268
Study: 25706515

Group type: EXPERIMENTAL
Intervention: New rehabilitation philosophy (new credo)
Number of subjects: 166
Study: 23394896

Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Baseline IL-6
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Baseline hsCRP
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: IP-10
Number of subjects: 772
Study: 21263308

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (10% Travasol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (5 healthy young males, 22 ± 3 years; 76 ± 15 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body protein breakdown
Number of subjects: 10
Study: 17919270

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplementation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 16945784

Group type: EXPERIMENTAL
Intervention: Nursing case management intervention
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Danger Assessment Screen
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Routine screening questions during pregnancy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Fear of being reported to child protective services
Number of subjects: 1000
Study: 12869382

Group type: EXPERIMENTAL
Intervention: Therapeutic infusions of immunoglobulins (Ig)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro with RBC suspensions containing fibrinogen, albumin, and Ig
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10708159

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Heated humidified water (HHW)
Number of subjects: 32
Study: 9094145

Group type: EXPERIMENTAL
Intervention: 20 mg/day selegiline
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 60 mg/day selegiline
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Selegiline (both doses)
Number of subjects: 36
Study: 7701235

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3113244

Group type: EXPERIMENTAL
Intervention: misoprostol 200 micrograms twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 32
Study: 29520867

Group type: EXPERIMENTAL
Intervention: Phenylephrine 50 μg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ephedrine 4 mg
Number of subjects: 80
Study: 28794283

Group type: EXPERIMENTAL
Intervention: Proinsulin peptide immunotherapy (intradermally every 2 or 4 weeks for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26026214

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23233356

Group type: EXPERIMENTAL
Intervention: Telephone contact with non-attendees offering an appointment to take a smear
Number of subjects: 4000
Study: 21052959

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 23
Study: 19546387

Group type: EXPERIMENTAL
Intervention: 40 microg/kg rFVIIa
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 80 microg/kg rFVIIa
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 16738287

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Laparotomy surgery
Number of subjects: 38
Study: 15517749

Group type: EXPERIMENTAL
Intervention: Dressing change procedure
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Reapplied wound-dressing products
Number of subjects: 133
Study: 11213933

Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention (one 90‐minute group session per week for 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9296310

Group type: EXPERIMENTAL
Intervention: Temocapril (10-40 mg once daily)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Atenolol (25-100 mg once daily)
Number of subjects: 472
Study: 7982016

Group type: EXPERIMENTAL
Intervention: Inosine (1.5 g daily, 3 x 500 mg for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study: 3549801

Group type: EXPERIMENTAL
Intervention: 0.1% topical minoxidil
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 1% topical minoxidil
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0.01% topical minoxidil
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 30055593

Group type: EXPERIMENTAL
Intervention: Practicing self‐medication
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Having more than three family members in the household
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Older age (≥55 years)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Being smear negative pulmonary tuberculosis
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Extrapulmonary tuberculosis
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Initial visit of general practitioners
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: More than one health care visit
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Widowed/divorced patients
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Lower level of education (illiterate)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Lower level of education (grade 1-8)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Diagnosis of TB using a chest X‐ray
Number of subjects: 382
Study: 26805699

Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Flexibility exercise
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 24971565

Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis (6 consecutive monthly doses)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (historic control, no palivizumab prophylaxis)
Number of subjects: 127
Study: 22296874

Group type: EXPERIMENTAL
Intervention: Health-At-Every-Size (HAES) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social support intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19789374

Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 6
Study: 18724035

Group type: EXPERIMENTAL
Intervention: Continuous-flushing method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balloon-occlusion method
Number of subjects: 40
Study: 15930349

Group type: EXPERIMENTAL
Intervention: ABI-007 (260 mg/m², 30 minutes; n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Taxol (175 mg/m², 3 hours; n = 13)
Number of subjects: 27
Study: 14617243

Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan procedure (Group 1, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stapled haemorrhoidectomy (Group 2, n = 25)
Number of subjects: 50
Study: 10795956

Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST, n = 61)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Exercise (BEX, n = 39)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Nicotine Gum (BNIC, n = 41)
Number of subjects: 141
Study: 8967905

Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nifedipine 10 mg t.i.d.
Number of subjects: 101
Study: 8447204

Group type: EXPERIMENTAL
Intervention: Low-dose adenosine (30 micrograms.kg‐1.min‐1 for 4 hours)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose adenosine
Number of subjects: 16
Study: 3082450

Group type: EXPERIMENTAL
Intervention: Intensive programme by general practitioners (educational consultation and four follow up visits)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Educational consultation and first follow up visit
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Completion of treatment programme and attendance at all follow up visits
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 200
Study: 29431452

Group type: EXPERIMENTAL
Intervention: Milkshake prime (Prime condition)
Number of subjects: 128

Group type: COMPARATOR
Intervention: No-Prime (Control condition)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both conditions (Prime and No-Prime)
Number of subjects: 128
Study: 29282948

Group type: EXPERIMENTAL
Intervention: Ultrasound guided injection group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Palpation guided injection group
Number of subjects: 120
Study: 25156227

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-person urine testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0
Study: 23408223

Group type: EXPERIMENTAL
Intervention: CoughStim™ (ultrasonic cough stimulator) at 0.58 MHz and 9 W unilaterally
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CoughStim™ (ultrasonic cough stimulator) at 0.58 MHz and 6 W bilaterally
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CoughStim™ (ultrasonic cough stimulator) at 0.54 MHz and 6 W bilaterally
Number of subjects: 22
Study: 21095483

Group type: EXPERIMENTAL
Intervention: lersivirine 500 mg BID
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg once daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg once daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: placebo once daily
Number of subjects: 66
Study: 18717168

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SE with Clearfil Flow FX (SE+FX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ED Primer II (ED)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil DC Core Automix (DC)
Number of subjects: 30
Study: 16230264

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 446
Study: 12854799

Group type: EXPERIMENTAL
Intervention: Group 1: Conventional framework design with parallel fibers (19 restorations)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Group 2: Modified framework design with parallel and woven fibers (22 restorations)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study: 10794048

Group type: EXPERIMENTAL
Intervention: Symptothermal double-check methods
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Symptothermal single-check methods
Number of subjects: 1328
Study: 9101834

Group type: EXPERIMENTAL
Intervention: Surgery + adjuvant IORT (28 Gy to the celiac axis)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Surgery (non-IORT)
Number of subjects: 115
Study: 1990191

Group type: EXPERIMENTAL
Intervention: 400 mg of acyclovir orally two times per day (suppressive therapy)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: 200 mg of acyclovir five times per day for 5 days (for recurrences)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Daily acyclovir therapy (suppressive therapy)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Acute therapy followed by suppressive therapy
Number of subjects: 525

Group type: COMPARATOR
Intervention: Baseline recurrence rate
Number of subjects: 525
Study: 6147703

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 347

Group type: COMPARATOR
Intervention: CNS prophylaxis
Number of subjects: 347
Study: 30471242

Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1636
Study: 30571697

Group type: EXPERIMENTAL
Intervention: Talking Prescriptions (Talking Rx) intervention including Daily Interactive Voice Response (IVR) call services, Daily tailored medication reminders, and Weekly lifestyle modification messages for 3 months.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Talking Prescriptions (Talking Rx) intervention for CVA patients.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 197
Study: 27402605

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 35

Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 35
Study: 24655537

Group type: COMPARATOR
Intervention: 30% oxygen (low‐oxygen group)
Number of subjects: 193

Group type: COMPARATOR
Intervention: 65% oxygen (high‐oxygen group)
Number of subjects: 193
Study: 22490713

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (25 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban (10 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No tirofiban (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban
Number of subjects: 120
Study: 20169258

Group type: EXPERIMENTAL
Intervention: Intra-articular administration of 10 mg of morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intra-articular administration of 20 mL of NS
Number of subjects: 50
Study: 17389291

Group type: EXPERIMENTAL
Intervention: Web-based GIOP intervention
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Web-based GIOP intervention (among 45 physicians completing all modules)
Number of subjects: 949
Study: 16093416

Group type: EXPERIMENTAL
Intervention: Intensive broad‐based home exercise program targeting flexibility, strength, balance, and endurance (30 half‐hour sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 11984100

Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pain management autobiographies (qualitative analysis)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Individual or family counseling or alternative pain management strategies
Number of subjects: 11
Study: 10460042

Group type: EXPERIMENTAL
Intervention: Testosterone transscrotal patch (6 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 8546997

Group type: EXPERIMENTAL
Intervention: Twice-weekly MPD-PUVA
Number of subjects: 83

Group type: COMPARATOR
Intervention: Three times-weekly skin typing-PUVA
Number of subjects: 83
Study: 2241822

Group type: EXPERIMENTAL
Intervention: Group A (first test while having pain)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (first test without pain)
Number of subjects: 30
Study: 318984

Group type: EXPERIMENTAL
Intervention: 50 mg LOX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg LOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31524140

Group type: EXPERIMENTAL
Intervention: Core-specific training (COR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Typical training (CON)
Number of subjects: 20
Study: 31339826

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (375 mg/m2, once every 8 weeks for 2 years)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Observation (no additional treatment)
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1018
Study: 28427883

Group type: EXPERIMENTAL
Intervention: Upright bag-mask
Number of subjects: 328

Group type: COMPARATOR
Intervention: Standard bag-mask
Number of subjects: 328
Study: 26521572

Group type: EXPERIMENTAL
Intervention: Head-point needle-retaining therapy + training (group A)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Training after acupuncture (group B)
Number of subjects: 66